$NWBO
NORTHWEST BIOTHERAPEUTICS INC

2023 Q2 Form 10-Q Financial Statement

#000141057823000976 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $201.0K $880.0K $403.0K
YoY Change -57.86% 118.36% 68.62%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.564M $6.983M $7.869M
YoY Change -4.63% -11.26% -38.93%
% of Gross Profit
Research & Development $6.214M $6.861M $4.820M
YoY Change -54.46% 42.34% -30.38%
% of Gross Profit
Depreciation & Amortization $350.0K $300.0K $100.0K
YoY Change -33.21% 200.0% 47.06%
% of Gross Profit
Operating Expenses $6.214M $6.861M $4.820M
YoY Change -71.2% 42.34% -30.38%
Operating Profit -$13.58M -$12.96M -$12.29M
YoY Change -35.65% 5.52% -37.22%
Interest Expense $1.302M $1.027M $1.903M
YoY Change -115.39% -46.03% 31.51%
% of Operating Profit
Other Income/Expense, Net -$871.0K $2.312M -$1.928M
YoY Change -89.84% -219.92% -112.48%
Pretax Income -$14.45M -$10.65M -$14.21M
YoY Change -51.3% -25.06% 244.75%
Income Tax
% Of Pretax Income
Net Earnings -$14.45M -$10.70M -$14.20M
YoY Change -51.3% -24.65% 244.41%
Net Earnings / Revenue -7188.06% -1215.91% -3523.57%
Basic Earnings Per Share -$0.01 -$0.01 -$0.01
Diluted Earnings Per Share -$0.01 -$0.01 -$0.01
COMMON SHARES
Basic Shares Outstanding 1.087B 1.073B 959.3K
Diluted Shares Outstanding 1.108M 1.075M 959.3K

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.424M $6.191M $6.963M
YoY Change -70.52% -11.09% -6.76%
Cash & Equivalents $1.424M $6.191M $6.963M
Short-Term Investments
Other Short-Term Assets $3.218M $3.300M $2.306M
YoY Change 37.11% 43.1% -59.89%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.642M $9.491M $9.269M
YoY Change -35.33% 2.4% -29.87%
LONG-TERM ASSETS
Property, Plant & Equipment $17.29M $13.57M $14.39M
YoY Change -4.41% -5.67% 1065.72%
Goodwill $626.0K $626.0K $626.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $361.0K $362.0K $349.0K
YoY Change 5.56% 3.72% -67.38%
Total Long-Term Assets $23.80M $23.38M $21.39M
YoY Change 16.97% 9.31% 11.15%
TOTAL ASSETS
Total Short-Term Assets $4.642M $9.491M $9.269M
Total Long-Term Assets $23.80M $23.38M $21.39M
Total Assets $28.44M $32.87M $30.66M
YoY Change 3.33% 7.22% -5.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.66M $20.64M $10.64M
YoY Change 33.01% 93.87% 1.91%
Accrued Expenses $385.0K $369.0K $325.0K
YoY Change 17.02% 13.54% 91.18%
Deferred Revenue
YoY Change
Short-Term Debt $1.858M $135.0K $0.00
YoY Change
Long-Term Debt Due $8.403M $10.47M $12.12M
YoY Change -15.91% -13.58% 410.4%
Total Short-Term Liabilities $39.93M $44.71M $130.0M
YoY Change -59.33% -65.61% -64.22%
LONG-TERM LIABILITIES
Long-Term Debt $15.74M $16.02M $16.16M
YoY Change -4.33% -0.89% -3.16%
Other Long-Term Liabilities $8.419M $4.370M $5.008M
YoY Change 84.06% -12.74% -9.93%
Total Long-Term Liabilities $24.16M $20.39M $21.17M
YoY Change 14.9% -3.69% -4.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $39.93M $44.71M $130.0M
Total Long-Term Liabilities $24.16M $20.39M $21.17M
Total Liabilities $64.09M $65.10M $151.2M
YoY Change -46.23% -56.94% -60.8%
SHAREHOLDERS EQUITY
Retained Earnings -$1.322B -$1.308B -$1.206B
YoY Change 8.41% -12.29%
Common Stock $1.259B $1.249B $1.085B
YoY Change 15.19% 6.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$61.03M -$55.98M -$120.5M
YoY Change
Total Liabilities & Shareholders Equity $28.44M $32.87M $30.66M
YoY Change 3.33% 7.22% -5.55%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$14.45M -$10.70M -$14.20M
YoY Change -51.3% -24.65% 244.41%
Depreciation, Depletion And Amortization $350.0K $300.0K $100.0K
YoY Change -33.21% 200.0% 47.06%
Cash From Operating Activities -$11.52M -$11.24M -$12.97M
YoY Change -22.37% -13.33% -2.12%
INVESTING ACTIVITIES
Capital Expenditures $1.249M $1.333M -$58.00K
YoY Change -406.13% -2398.28% -78.03%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.249M -$1.333M -$58.00K
YoY Change 206.13% 2198.28% -78.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.638M 12.58M 3.920M
YoY Change -17.03% 220.97% -63.57%
NET CHANGE
Cash From Operating Activities -11.52M -11.24M -12.97M
Cash From Investing Activities -1.249M -1.333M -58.00K
Cash From Financing Activities 8.638M 12.58M 3.920M
Net Change In Cash -4.132M -774.0K -8.206M
YoY Change -14.59% -90.57% 226.28%
FREE CASH FLOW
Cash From Operating Activities -$11.52M -$11.24M -$12.97M
Capital Expenditures $1.249M $1.333M -$58.00K
Free Cash Flow -$12.77M -$12.57M -$12.91M
YoY Change -11.52% -2.61% -0.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001072379
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NONE
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1068400000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1083100000
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-35737
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
NORTHWEST BIOTHERAPEUTICS, INC
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3306718
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
4800 Montgomery Lane
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 800
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bethesda
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20814
CY2023Q1 dei City Area Code
CityAreaCode
240
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
497-9024
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
NWBO
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1086771876
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6191000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6965000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3300000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2460000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
9491000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
9425000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13570000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13418000
CY2023Q1 nwbo Constructions In Progress Net
ConstructionsInProgressNet
3321000
CY2022Q4 nwbo Constructions In Progress Net
ConstructionsInProgressNet
2028000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4209000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4189000
CY2023Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1292000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1292000
CY2023Q1 us-gaap Goodwill
Goodwill
626000
CY2022Q4 us-gaap Goodwill
Goodwill
626000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
362000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
345000
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
23380000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
21898000
CY2023Q1 us-gaap Assets
Assets
32871000
CY2022Q4 us-gaap Assets
Assets
31323000
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11892000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10687000
CY2023Q1 nwbo Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
8744000
CY2022Q4 nwbo Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
6955000
CY2023Q1 nwbo Convertible Notes Payable Net Current
ConvertibleNotesPayableNetCurrent
135000
CY2022Q4 nwbo Convertible Notes Payable Net Current
ConvertibleNotesPayableNetCurrent
135000
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
10471000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
15403000
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8451000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8668000
CY2023Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1445000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
80559000
CY2023Q1 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
2616000
CY2022Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
2566000
CY2023Q1 nwbo Share Liability
ShareLiability
585000
CY2022Q4 nwbo Share Liability
ShareLiability
678000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
369000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
354000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
44708000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
126005000
CY2023Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
16019000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5991000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4370000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4370000
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
20389000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
10361000
CY2023Q1 us-gaap Liabilities
Liabilities
65097000
CY2022Q4 us-gaap Liabilities
Liabilities
136366000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1700000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1700000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1083100000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1068400000
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1083000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1068000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1248397000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1164885000
CY2023Q1 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
79000
CY2022Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
79000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1307774000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1297122000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2395000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3145000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-55978000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-128103000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32871000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31323000
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
880000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
403000
CY2023Q1 us-gaap Revenues
Revenues
880000
CY2022Q1 us-gaap Revenues
Revenues
403000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6861000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4820000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6983000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7869000
CY2023Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
13844000
CY2022Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12689000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12964000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12286000
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3880000
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
540000
CY2023Q1 nwbo Fair Value Adjustment Of Share Liability
FairValueAdjustmentOfShareLiability
-52000
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1408000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
410000
CY2023Q1 us-gaap Interest Expense
InterestExpense
1027000
CY2022Q1 us-gaap Interest Expense
InterestExpense
1903000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
919000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-975000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2312000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1928000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10652000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14214000
CY2023Q1 nwbo Deemed Dividend Related To Warrant Modification
DeemedDividendRelatedToWarrantModification
395000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11047000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14214000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
750000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-808000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11797000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13406000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1074902
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
959251
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1074902
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
959251
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-128103000
CY2023Q1 nwbo Temporary Equity Stock Issued During Period Value Common Stock Warrant Exercise
TemporaryEquityStockIssuedDuringPeriodValueCommonStockWarrantExercise
2617000
CY2023Q1 nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
248000
CY2023Q1 nwbo Adjustments To Additional Paid In Capital Reclassification Of Warrant Liabilities To Stockholders Deficit
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesToStockholdersDeficit
76258000
CY2023Q1 nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
5616000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
918000
CY2023Q1 nwbo Adjustments To Additional Paid In Capital Reclass Earned But Unissued Milestone Shares From Equity To Liability
AdjustmentsToAdditionalPaidInCapitalReclassEarnedButUnissuedMilestoneSharesFromEquityToLiability
2130000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10652000
CY2023Q1 nwbo Adjustments To Additional Paid In Capital Warrants Modfication
AdjustmentsToAdditionalPaidInCapitalWarrantsModfication
395000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
395000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-750000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-55978000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-123991000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3364000
CY2022Q1 nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
4185000
CY2022Q1 nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
7715000
CY2022Q1 nwbo Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised
AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised
4000
CY2022 nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
987000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-617000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14214000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
808000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-120525000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10652000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14214000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
335000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
CY2023Q1 nwbo Amortization Of Debt Discount
AmortizationOfDebtDiscount
552000
CY2022Q1 nwbo Amortization Of Debt Discount
AmortizationOfDebtDiscount
809000
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3880000
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
540000
CY2023Q1 nwbo Fair Value Adjustment Of Share Liability
FairValueAdjustmentOfShareLiability
-52000
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1408000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
410000
CY2023Q1 nwbo Operating Lease Roa
OperatingLeaseRoa
67000
CY2022Q1 nwbo Operating Lease Roa
OperatingLeaseRoa
60000
CY2023Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
933000
CY2022Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
617000
CY2023Q1 us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-533000
CY2022Q1 us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
636000
CY2023Q1 nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
709000
CY2022Q1 nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
199000
CY2023Q1 nwbo Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
16000
CY2022Q1 nwbo Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
-679000
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
975000
CY2022Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
795000
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-341000
CY2022Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-694000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
37000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
30000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11239000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12967000
CY2023Q1 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
1333000
CY2022Q1 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
58000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1333000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-58000
CY2022Q1 nwbo Proceeds From Issuance Of Capital Stock And Warrants
ProceedsFromIssuanceOfCapitalStockAndWarrants
3140000
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
248000
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4185000
CY2023Q1 nwbo Payments To Investors
PaymentsToInvestors
-50000
CY2023Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10000000
CY2022Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
600000
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
101000
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4005000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12582000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3920000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-784000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
899000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-774000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8206000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6965000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15169000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6191000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6963000
CY2023Q1 nwbo Stock Issued During Period Value For Warrant And Stock Options Cashless Exercise
StockIssuedDuringPeriodValueForWarrantAndStockOptionsCashlessExercise
1000
CY2022Q1 nwbo Reclassification Of Warrant Liabilities Related To Warrants Exercised For Cash
ReclassificationOfWarrantLiabilitiesRelatedToWarrantsExercisedForCash
7715000
CY2023Q1 nwbo Reclassification Of Warrant Liabilities To Stockholders Deficit Non Cash Investing And Financing Activities
ReclassificationOfWarrantLiabilitiesToStockholdersDeficitNonCashInvestingAndFinancingActivities
76258000
CY2022Q1 nwbo Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised
AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised
4000
CY2023Q1 nwbo Reclass Earned But Unissued Milestone Shares From Equity To Liability Non Cash Investing And Financing Activities
ReclassEarnedButUnissuedMilestoneSharesFromEquityToLiabilityNonCashInvestingAndFinancingActivities
2130000
CY2023Q1 nwbo Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received
IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived
5616000
CY2022Q1 nwbo Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received
IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived
987000
CY2023Q1 nwbo Issuance Of Convertible Preferred Stock In Lieu Of Debt Redemption
IssuanceOfConvertiblePreferredStockInLieuOfDebtRedemption
806000
CY2023Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2617000
CY2023Q1 nwbo Capital Expenditures Included In Accounts Payable
CapitalExpendituresIncludedInAccountsPayable
1013000
CY2022Q1 nwbo Capital Expenditures Included In Accounts Payable
CapitalExpendituresIncludedInAccountsPayable
86000
CY2022Q1 nwbo Capital Expenditures Included In Accounts Payable And Accrued Expenses To Related Parties And Affiliates
CapitalExpendituresIncludedInAccountsPayableAndAccruedExpensesToRelatedPartiesAndAffiliates
11000
CY2022Q1 nwbo Reclassification Between Shares Payable And Equity
ReclassificationBetweenSharesPayableAndEquity
250000
CY2023Q1 nwbo Deemed Dividend Related To Warrant Modification Non Cash Investing And Financing Activities
DeemedDividendRelatedToWarrantModificationNonCashInvestingAndFinancingActivities
395000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2300000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
90712000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
538000
CY2023Q1 nwbo Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Debt Redemption
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDebtRedemption
-683000
CY2023Q1 nwbo Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification For Warrants Exercised For Cash
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationForWarrantsExercisedForCash
76258000
CY2023Q1 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-3828000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10700000
CY2023Q1 us-gaap Payments For Operating Activities
PaymentsForOperatingActivities
11200000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In preparing condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">On an ongoing basis, the Company evaluates its estimates and judgments, including valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets, and whether impairment charges may apply. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic (“COVID-19”) and the COVID-19 control responses.</span></p>
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
10481000
CY2023Q1 nwbo Warrant Liability Related To Purchase Shares In Future Raise Of Capital
WarrantLiabilityRelatedToPurchaseSharesInFutureRaiseOfCapital
1400000
CY2023Q1 nwbo Reclassification Of Fair Value Of Warrant Liability Into Additional Paid In Capital
ReclassificationOfFairValueOfWarrantLiabilityIntoAdditionalPaidInCapital
76300000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1200000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1700000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 nwbo Number Of Warrants To Purchase Shares Of Common Stock Reclassified From Liability To Equity
NumberOfWarrantsToPurchaseSharesOfCommonStockReclassifiedFromLiabilityToEquity
141000000
CY2023Q1 nwbo Reclassification Of Fair Value Of Warrant Liability Into Additional Paid In Capital
ReclassificationOfFairValueOfWarrantLiabilityIntoAdditionalPaidInCapital
76300000
CY2023Q1 nwbo Warrant Liability Related To Purchase Shares In Future Raise Of Capital
WarrantLiabilityRelatedToPurchaseSharesInFutureRaiseOfCapital
1400000
CY2023Q1 nwbo Modification Of Equity Classified Warrants
ModificationOfEquityClassifiedWarrants
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Modification of Equity Classified Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A change in the terms or conditions of a warrant is accounted for as a modification. For a warrant modification accounted for under ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant and the fair value of the original warrant immediately before its terms are modified, with each measured on the modification date. The accounting for incremental fair value of the modified warrants over the original warrants is based on the specific facts and circumstances related to the modification. When a modification is directly attributable to an equity offering, the incremental change in fair value of the warrants is accounted for as an equity issuance cost. When a modification is directly attributable to a debt offering, the incremental change in fair value of the warrants is accounted for as a debt discount or debt issuance cost. For all other modifications, the incremental change in fair value is recognized as a deemed dividend.</p>
CY2023Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1445000
CY2023Q1 nwbo Contingent Payable Derivative Liability
ContingentPayableDerivativeLiability
8451000
CY2023Q1 nwbo Share Liability
ShareLiability
585000
CY2023Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
10481000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
80559000
CY2022Q4 nwbo Embedded Derivative Redemption Option Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeRedemptionOptionFairValueOfEmbeddedDerivativeLiability
807000
CY2022Q4 nwbo Contingent Payable Derivative Liability
ContingentPayableDerivativeLiability
8668000
CY2022Q4 nwbo Share Liability
ShareLiability
678000
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
90712000
CY2023Q1 nwbo Fair Value Liabilities Transfer Between Levels Amount
FairValueLiabilitiesTransferBetweenLevelsAmount
0
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
933000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
617000
CY2023Q1 nwbo Number Of Milestones Completed
NumberOfMilestonesCompleted
500000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
800000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
301263000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.34
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
135225000
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1325000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.33
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
299938000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.34
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M18D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
90543000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
281009000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.33
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y9M18D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
85618000
CY2023Q1 nwbo Share Based Compensation Arrangement By Share Based Payment Award Period Of Notice For Exercising Any Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfNoticeForExercisingAnyOption
P61D
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13570000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13418000
CY2023Q1 us-gaap Depreciation
Depreciation
300000
CY2022Q1 us-gaap Depreciation
Depreciation
100000
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
28810000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2185000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
26625000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
22454000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1732000
CY2022Q4 nwbo Fair Value Of Embedded Conversion Option
FairValueOfEmbeddedConversionOption
807000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
21529000
CY2023Q1 us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
700000
CY2023Q1 nwbo Accrued Share Liabilities
AccruedShareLiabilities
500000
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost
GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
1300000
CY2023Q1 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
800000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
475673000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
513648000
CY2023Q1 nwbo Percentage Of Margin
PercentageOfMargin
0.15
CY2023Q1 nwbo Amount Recognized And Expensed Related To Current Cash Component
AmountRecognizedAndExpensedRelatedToCurrentCashComponent
1000000.0
CY2023Q1 nwbo Number Of Milestones Completed
NumberOfMilestonesCompleted
2
CY2023Q1 nwbo Shares Related To Completed Milestones
SharesRelatedToCompletedMilestones
3000000.0
CY2023Q1 nwbo Shares Related To Completed Milestones
SharesRelatedToCompletedMilestones
3000000.0
CY2023Q1 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
2100000
CY2023Q1 nwbo Stock Based Compensation Related To Achieved Milestone
StockBasedCompensationRelatedToAchievedMilestone
500000
CY2022 nwbo Stock Based Compensation Related To Achieved Milestone
StockBasedCompensationRelatedToAchievedMilestone
1600000
CY2023Q1 nwbo Amount Recognized And Expensed Not Yet Paid
AmountRecognizedAndExpensedNotYetPaid
500000
CY2023Q1 nwbo Amount Related To Future Cash Milestone Payments Anticipated To Achieve And Earn
AmountRelatedToFutureCashMilestonePaymentsAnticipatedToAchieveAndEarn
200000
CY2023Q1 nwbo Fair Value Of Future Shares Milestone Payments Anticipate To Achieve And Earn
FairValueOfFutureSharesMilestonePaymentsAnticipateToAchieveAndEarn
100000
CY2023Q1 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
4675000
CY2022Q1 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
2829000
CY2023Q1 us-gaap Sublease Income
SubleaseIncome
36000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1200000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1700000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
200000
CY2023Q1 nwbo Stock Issued During Period Shares Warrant Exercises
StockIssuedDuringPeriodSharesWarrantExercises
800000
CY2023Q1 nwbo Debt Instrument Redemption Shares Issued
DebtInstrumentRedemptionSharesIssued
8300000
CY2023Q1 nwbo Debt Instrument Redemption Amount
DebtInstrumentRedemptionAmount
4100000
CY2023Q1 nwbo Debt Instrument Redemption Amount Interest
DebtInstrumentRedemptionAmountInterest
200000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
141048
CY2022Q4 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.31
CY2022 nwbo Class Of Warrant Or Right Outstanding Remaining Contractual Term
ClassOfWarrantOrRightOutstandingRemainingContractualTerm
P1Y5M15D
CY2023Q1 nwbo Number Of Warrants Warrants Exercised For Cash
NumberOfWarrantsWarrantsExercisedForCash
767
CY2023Q1 nwbo Weighted Average Exercise Price Exercised For Cash
WeightedAverageExercisePriceExercisedForCash
0.32
CY2023Q1 nwbo Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
38
CY2023Q1 nwbo Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
0.34
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
140243
CY2023Q1 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.31
CY2023Q1 nwbo Class Of Warrant Or Right Outstanding Remaining Contractual Term
ClassOfWarrantOrRightOutstandingRemainingContractualTerm
P1Y5M1D
CY2023Q1 nwbo Class Of Warrant Or Right Extended In Suspension
ClassOfWarrantOrRightExtendedInSuspension
97000000
CY2023Q1 us-gaap Lease Practical Expedient Lessor Single Lease Component
LeasePracticalExpedientLessorSingleLeaseComponent
true
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
4700000
CY2023Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P20Y
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4200000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
209000
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
23000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
4000
CY2023Q1 us-gaap Sublease Income
SubleaseIncome
36000
CY2023Q1 us-gaap Lease Cost
LeaseCost
200000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
225000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
152000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
13000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
10000
CY2022Q1 us-gaap Sublease Income
SubleaseIncome
36000
CY2022Q1 us-gaap Lease Cost
LeaseCost
138000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
239000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
688000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
823000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
618000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
618000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
618000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
6783000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10148000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5409000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
4739000
CY2023Q1 nwbo Original Term Of Agreement
OriginalTermOfAgreement
P8M
CY2022Q3 nwbo Litigation Settlement Waiver Of Penalty
LitigationSettlementWaiverOfPenalty
135000
CY2022Q3 nwbo Litigation Settlement Waiver Of Penalty
LitigationSettlementWaiverOfPenalty
147000
CY2023Q1 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
377000
CY2023Q1 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
410000

Files In Submission

Name View Source Status
0001410578-23-000976-index-headers.html Edgar Link pending
0001410578-23-000976-index.html Edgar Link pending
0001410578-23-000976.txt Edgar Link pending
0001410578-23-000976-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nwbo-20230331.xsd Edgar Link pending
nwbo-20230331x10q.htm Edgar Link pending
nwbo-20230331xex31d1.htm Edgar Link pending
nwbo-20230331xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nwbo-20230331_cal.xml Edgar Link unprocessable
nwbo-20230331_def.xml Edgar Link unprocessable
nwbo-20230331_lab.xml Edgar Link unprocessable
nwbo-20230331_pre.xml Edgar Link unprocessable
nwbo-20230331x10q_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending